Benjamin Nacev

16PUBLICATIONS
72CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Tumour immunologyMolecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Dec 03, 2025
ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival.

Kathryn Demanelis, Julia Leix, Melissa A Burgess

|Sep 05, 2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.

Benjamin A Nacev, Martina Bradic, Hyung Jun Woo

|May 07, 2025
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.

Emily K Slotkin, Audrey Mauguen, Filemon S Dela Cruz

|Oct 22, 2024
Author Correction: Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation.

Benjamin A Nacev, Yakshi Dabas, Matthew R Paul

|Jun 17, 2024
Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation.

Benjamin A Nacev, Yakshi Dabas, Matthew R Paul

|Mar 13, 2024
ATRX guards against aberrant differentiation in mesenchymal progenitor cells.

Yan Fang, Douglas Barrows, Yakshi Dabas

Pageof 3

Frequent Collaborators

8 joint publications

William D Tap

8 joint publications

Evan Rosenbaum

8 joint publications

Ciara M Kelly

7 joint publications

Sandra P D'Angelo